{
    "root": "09016810-23d1-4df1-831d-cc346dee1b52",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "isosorbide dinitrate and hydralazine hydrochloride",
    "value": "20240701",
    "ingredients": [
        {
            "name": "HYDRALAZINE HYDROCHLORIDE",
            "code": "FD171B778Y"
        },
        {
            "name": "ISOSORBIDE DINITRATE",
            "code": "IA7306519N"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "isosorbide dinitrate hydralazine hydrochloride tablets combination isosorbide dinitrate , nitrate vasodilator , hydralazine hydrochloride , arteriolar vasodilator , indicated : treatment heart failure adjunct therapy standard therapy self-identified black patients improve survival , prolong time hospitalization heart failure improve patient-reported functional status ( 1.1 ) limitations : little experience patients nyha class iv heart failure ( 1.2 )",
    "contraindications": "isosorbide dinitrate hydralazine hydrochloride tablets initiated dose one isosorbide dinitrate hydralazine hydrochloride tablet , three times day . titrate maximum two tablets three times daily , tolerated . although titration isosorbide dinitrate hydralazine hydrochloride tablets rapid ( 3-5 days ) , patients may experience side effects may take longer reach maximum tolerated dose . may decreased little one-half isosorbide dinitrate hydralazine hydrochloride tablet three times day intolerable side effects occur . efforts made titrate soon side effects subside .",
    "warningsAndPrecautions": "isosorbide dinitrate hydralazine hydrochloride tablets contain 20 mg isosorbide dinitrate 37.5 mg hydralazine hydrochloride . biconvex , approximately 8 mm diameter , scored , film-coated , orange tablets debossed `` 20 `` one side score `` n `` side . ndc 72162-2343-9 : 90 tablets bottle store 25°c ( 77°f ) , excursions permitted 15-30°c ( 59-86°f ) . [ usp controlled room temperature . ] keep bottles tightly closed . protect light . dispense light-resistant , tight container . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "isosorbide dinitrate hydralazine hydrochloride tablets contraindicated patients allergic organic nitrates . isosorbide dinitrate hydralazine hydrochloride tablets patients taking pde-5 inhibitors , avanafil , sildenafil , tadalafil , vardenafil . concomitant cause severe hypotension , syncope , myocardial ischemia [ ( 7.1 ) ] . isosorbide dinitrate hydralazine hydrochloride tablets patients taking soluble guanylate cyclase ( sgc ) stimulator riociguat . concomitant cause hypotension .",
    "indications_original": "Isosorbide dinitrate and hydralazine hydrochloride tablets are a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 )",
    "contraindications_original": "Isosorbide dinitrate and hydralazine hydrochloride tablets should be initiated at a dose of one isosorbide dinitrate and hydralazine hydrochloride tablet, three times a day. Titrate to a maximum of two tablets three times daily, if tolerated.\n                  Although titration of isosorbide dinitrate and hydralazine hydrochloride tablets can be rapid (3-5 days), some patients may experience side effects and may take longer to reach their maximum tolerated dose. The dosage may be decreased to as little as one-half isosorbide dinitrate and hydralazine hydrochloride tablet three times a day if intolerable side effects occur. Efforts should be made to titrate up as soon as side effects subside.",
    "warningsAndPrecautions_original": "Isosorbide dinitrate and hydralazine hydrochloride tablets contain 20 mg of isosorbide dinitrate and 37.5 mg of hydralazine hydrochloride. They are biconvex, approximately 8 mm in diameter, scored, film-coated, orange tablets debossed \"20\" on one side over the score and \"N\" on the other side.\n                  \n                  \n                     NDC 72162-2343-9: 90 Tablets in a BOTTLE\n                  \n                  Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature.] Keep bottles tightly closed.\n                  Protect from light. Dispense in a light-resistant, tight container.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Isosorbide dinitrate and hydralazine hydrochloride tablets are contraindicated in patients who are allergic to organic nitrates.\n                  Do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking PDE-5 inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1)].\n                  Do not use isosorbide dinitrate and hydralazine hydrochloride tablets in patients who are taking the soluble guanylate cyclase (sGC) stimulator riociguat. Concomitant use can cause hypotension."
}